Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2018 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Granted First Gender Specific Patent for Gimoti™

SOLANA BEACH, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 26, 2018 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

SOLANA BEACH, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 07, 2018 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ doseAnnounced discovery of sex-based pharmacokinetic differences for Gimoti™Met with FDA...
March 06, 2018 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

SOLANA BEACH, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 05, 2018 07:30 ET | Source: Evoke Pharma, Inc.

FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

SOLANA BEACH, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
February 21, 2018 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results

SOLANA BEACH, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that...
February 15, 2018 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™

SOLANA BEACH, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
November 14, 2017 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2017 Results and Highlights

Announced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti™505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filingPartnered with the Patheon...
November 09, 2017 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific

SOLANA BEACH, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
November 07, 2017 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results

SOLANA BEACH, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that...